<DOC>
	<DOC>NCT01395992</DOC>
	<brief_summary>Participants who have completed the 3-week trial P05691 (NCT00764478) can be screened for eligibility for this 26-week extension study in which they will continue treatment. The primary purpose of this trial is to evaluate the long-term safety of asenapine.</brief_summary>
	<brief_title>Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Inclusion criteria: Each participant must have completed the shortterm trial P05691, and be judged by the investigator to likely benefit from continued treatment Each participant must have demonstrated an acceptable degree of compliance with trial medication, visits, and other requirements in the shortterm trial P05691 Exclusion criteria: A participant must not have had any adverse event or other clinically significant finding(s) in the shortterm trial P05691 that would prohibit the subject's continuation into this longterm extension trial A participant must not have any newly diagnosed or discovered psychiatric condition that would have excluded the subject from participation in the shortterm trial P05691 A participant must not be at imminent risk of selfharm or harm to others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>